Insilico, SK Launch Up-to-$2.5B Neuroimmune AI Drug Collaboration
Insilico, SK Launch Up-to-$2.5B Neuroimmune AI Drug Collaboration
Publish Date: 2026-06-28 16:17:00
Source Domain: www.genengnews.com
- Insilico Medicine has partnered with SK Biopharmaceuticals to use its AI-based Pharma.AI platform for discovering new drug candidates targeting disorders in the neuroimmune area of the central nervous system (CNS), potentially generating up to $2.5 billion for Insilico.
- The collaboration will leverage Insilico’s strengths in target validation, generative chemistry, and molecule optimization, with SK providing its expertise in development and clinical capabilities for neuroimmune disorders.
- SK Biopharmaceuticals plans to drive the late-stage development and commercialization of these new therapies.
- Insilico Medicine, known for its focus on longevity-related targets, is also advancing a pipeline of over 40 programs across various indications, including cancer and neurodegenerative diseases.
- Notably, Insilico is undergoing clinical studies for rentosertib, a drug targeting idiopathic pulmonary fibrosis (IPF), which has shown promising early results.
- This partnership signifies a significant milestone for Insilico, as it marks its second multi-billion-dollar collaboration in 2024, following a similar agreement with Eli Lilly.
- Alex Zhavoronkov, Insilico’s CEO and co-founder, emphasized that the company is leveraging its cutting-edge AI technology to transition from an experimental tool to a practical drug discovery method, highlighting their focus on using AI to identify and develop new drugs efficiently.
